Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEV-285
- Development stage
- Preclinical
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TEV-285 is a biosimilar monoclonal antibody candidate developed by Teva Pharmaceutical Industries, currently in preclinical development. It is designed as a biosimilar to the reference product Perjeta (pertuzumab), which targets the human epidermal growth factor receptor 2 (HER2). TEV-285 specifically binds to the extracellular dimerization domain (subdomain II) of HER2, sterically hindering its ability to form heterodimers with other members of the HER family, such as EGFR, HER3, and HER4. This inhibition of dimerization prevents the activation of downstream signaling pathways, including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways, which are critical for the proliferation and survival of HER2-overexpressing cancer cells. The primary intended indication for TEV-285 is the treatment of HER2-positive breast cancer.
- Other names
- pertuzumab biosimilar - Teva
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TEV-285.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEV-285.